Table 50Five-year relative cancer survival rates for selected cancer sites, by race and sex: United States, selected geographic areas, selected years 1975–1977 through 1999–2005

[Data are based on the Surveillance, Epidemiology, and End Results (SEER) Program’s 9 population-based cancer registries]

Click here for spreadsheet version

WhiteBlack or African American
Sex and site1975–19771981–19831987–19891996–19981999–20051975–19771981–19831987–19891996–19981999–2005
Both sexesPercent of patients
All sites51.052.857.865.669.139.739.643.755.559.4
Oral cavity and pharynx54.655.056.661.164.436.231.834.436.346.1
Esophagus5.67.611.114.919.83.14.36.410.112.5
Stomach14.816.919.121.025.316.317.220.023.826.1
Colon51.756.761.863.867.446.449.753.354.755.6
Rectum49.453.759.664.769.445.040.653.756.561.0
Pancreas2.62.83.44.45.72.33.75.93.65.3
Lung and bronchus12.813.913.815.416.611.511.711.212.712.9
Urinary bladder74.579.381.580.782.650.660.163.362.367.8
Non-Hodgkin’s lymphoma48.452.852.861.070.149.050.447.454.459.9
Leukemia36.040.245.650.854.833.534.236.739.146.3
Male
All sites43.347.653.364.769.332.734.338.857.262.2
Oral cavity and pharynx54.153.854.460.064.129.726.430.131.441.0
Esophagus4.96.811.414.419.61.63.65.08.510.2
Stomach13.716.116.119.123.416.416.817.221.025.1
Colon51.057.562.663.767.945.545.951.655.655.0
Rectum48.452.359.863.569.541.938.349.554.760.2
Pancreas2.72.33.25.06.02.74.05.53.33.6
Lung and bronchus11.512.312.513.514.410.810.511.111.011.1
Prostate gland69.874.985.498.099.961.363.772.294.297.9
Urinary bladder75.580.483.581.783.556.865.468.165.171.5
Non-Hodgkin’s lymphoma47.852.649.258.768.442.649.542.252.355.0
Leukemia35.140.047.650.655.630.433.435.039.546.8
Female
All sites57.857.662.166.468.947.145.648.953.556.2
Colon52.256.161.063.966.946.852.454.554.055.9
Rectum50.555.359.566.369.347.542.957.858.261.6
Pancreas2.33.23.53.85.32.03.36.13.76.6
Lung and bronchus15.917.115.817.719.114.015.111.515.215.2
Melanoma of skin86.787.791.593.295.3 * * 90.478.677.6
Breast75.977.785.489.691.362.264.071.376.578.9
Cervix uteri70.769.073.774.673.165.061.658.165.364.8
Corpus uteri189.284.085.686.987.261.854.259.164.163.1
Ovary36.540.339.945.145.543.138.935.241.337.2
Non-Hodgkin’s lymphoma48.953.157.263.772.156.151.553.757.765.6
*

Data for population groups with fewer than 25 cases are not shown because estimates are considered unreliable.

1

Includes corpus uteri only cases and not uterus, not elsewhere specified cases.

NOTES: Rates are based on followup of patients through 2006. The rate is the ratio of the observed survival rate for the patient group to the expected survival rate for persons in the general population similar to the patient group with respect to age, sex, race, and calendar year of observation. It estimates the chance of surviving the effects of cancer. The site variable distinguishes Kaposi Sarcoma and Mesothelioma as individual cancer sites. As a result, Kaposi Sarcoma and Mesothelioma cases are excluded from each of the sites shown except all sites combined. The race groups, white and black, include persons of Hispanic and non-Hispanic origin. Due to death certificate race-ethnicity classification and other methodological issues related to developing life tables, survival rates for race-ethnicity groups other than white and black are not calculated. Data have been revised and differ from previous editions of Health, United States. Data for additional years are available. See Appendix III.

SOURCE: National Institutes of Health, National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. Available from: http://www​.seer.cancer.gov.

From: Trend Tables

Cover of Health, United States, 2009
Health, United States, 2009: With Special Feature on Medical Technology.
National Center for Health Statistics (US) .
Hyattsville (MD): National Center for Health Statistics (US); 2010 Jan.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.